129688-76-2

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 129688-70-6 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinoline-carboxylic Acid Methyl Ester 
• 584-08-7 potassium carbonate 
• 88-65-3 2-bromobenzoic-acid 
• 129689-07-2 (2-Carboxyphenyl)propanedioic Acid Dimethyl Ester 
• 137643-17-5 2-(2-Chlorocarbonyl-phenyl)-malonic acid dimethyl ester 
• 112734-22-2 4-bromo-2-fluorobenzylamine 

Downstream Products

• 137643-14-2 2-(4-Bromo-2-fluoro-benzyl)-4-chlorocarbonylmethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid methyl ester 
• 129688-94-4 4-(2-amino-2-oxoethyl)-2-<(4-bromo-2-fluorophenyl)methyl>-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic acid methyl ester 
• 129688-82-0 2-<(4-bromo-2-fluorophenyl)methyl>-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic acid 

Relevant academic research and scientific papers

Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-Bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1

The high concentrations of plasma glucose formed during diabetic hyperglycemia rapidly translate into high levels of glucose in tissues where glucose uptake is independent of insulin. In these tissues that include the lens, retina, nerve, and kidney, this

SPIRO-PYRIDAZINES AND ANALOGS THEREOF USEFUL AS ALDOSE REDUCTASE INHIBITORS

This invention relates to spiro-pyridazines, to processes for their preparation, to methods for using the compounds, and to pharmaceutical prepartions thereof. The compounds have pharmaceutical properties which render them beneficial for the prevention or

SPIRO-LACTAMS AND ANALOGS THEREOF USEFUL AS ALDOSE REDUCTASE INHIBITORS

This invention relates to spiro-lactams and their pharmaceutically acceptable salts thereof, to processes for their preparation, to methods for using the compounds, and to pharmaceutical preparations thereof. The compounds have pharmaceutical properties w

1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors

This invention relates to 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones of structural formula (I) STR1 wherein: R1 and R2 are independently hydrogen, alkyl containing 1 to 6 carbon atoms, halogen, lower alko

N'-ALKYL-SPIRO-ISOQUINOLINE-PYRROLIDINE TETRONES AND ANALOGS THEREOF USEFUL AS ALDOSE REDUCTASE INHIBITORS

This invention relates to N'-alkyl-spiro-isoquinoline-pyrrolidine tetrones and their pharmaceutically acceptable salts thereof, to processes for their preparation, to methods for using the compounds, and to pharmaceutical perparations thereof. The compoun

ALKYLIDENE ANALOGS OF 1'-AMINOSPIRO[ISOQUINOLINE-4(1H),3'-PYRROLIDINE]-1,2',3,5'(2H)-TETRONES USEFUL AS ALDOSE REDUCTASE INHIBITORS

This invention relates to alkylidene analogs of 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones, represented by formula (I): to processes for the preparation, to methods for using the compounds, and to pharmaceutical preparations t